Genelux Corporation Announces $33 Million Private Placement
15 mai 2023 07h00 HE
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 shares...
The Benchmark Company Announces Upcoming Healthcare House Call VIRTUAL One-on-One Investor Conference
27 avr. 2023 09h00 HE
|
The Benchmark Company
NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- The Benchmark Company is pleased to announce our upcoming Healthcare House Call VIRTUAL One-on-One Investor Conference to be held Tuesday, May 23, 2023....
Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023
23 mars 2023 07h00 HE
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical company focused on developing a...
Global Oncolytic Virus Therapy Clinical Pipeline Insight 2028
20 mars 2023 03h21 HE
|
KuicK Research
Delhi, March 20, 2023 (GLOBE NEWSWIRE) -- Global Oncolytic Virus Immunotherapy Market & Clinical Trials Insight 2028 Report Overview: Global Oncolytic Virus Immunotherapy Therapy Market...
At 9.6% CAGR, Global Cancer Gene Therapy Market Size Estimated to Cross USD 3.99 Billion Value By 2030: Polaris Market Research
24 févr. 2023 07h54 HE
|
Polaris Market Research & Consulting LLP
New York, NY, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Polaris Market Research has published a new research report titled “Cancer Gene Therapy Market Share, Size, Trends, Industry Analysis Report, By...
Global Cancer Gene Therapy Market to Reach $7.8 Billion by 2030
02 févr. 2023 14h16 HE
|
ReportLinker
New York, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Cancer Gene Therapy Industry" - https://www.reportlinker.com/p05956210/?utm_source=GNW Food...
Genelux Corporation Announces Pricing of Initial Public Offering
25 janv. 2023 21h00 HE
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux” or “the Company”), a clinical-stage immunotherapy company focused on developing a pipeline of...
Insights on the Oncolytic Virus Immunotherapy Global Market to 2028 - Featuring Key Players AdCure Bio, BioVex, Calidi Biotherapeutics, Takara Bio and Others
13 déc. 2022 06h08 HE
|
Research and Markets
Dublin, Dec. 13, 2022 (GLOBE NEWSWIRE) -- The "Global Oncolytic Virus Immunotherapy Market and Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering. The global...
Fallopian Tube Cancer Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
14 nov. 2022 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Fallopian Tube Cancer Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight Abnormal...
Genelux Corporation Initiates a Pivotal Phase 3 Trial, Evaluating Olvi-Vec for the treatment of Platinum-Resistant/Refractory Ovarian Cancer
21 sept. 2022 08h06 HE
|
Genelux Corporation
The Company’s first Phase 3 trial, OnPrime (GOG-3076), will evaluate Olvi-Vec, a modified vaccinia virus, as immunochemotherapy Trial will be conducted as a collaboration between Genelux and The...